Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis

Transplant International

Volumn 20, Issue 6, 2007, Pages 558-562

  Gossmann, Jan ^a,b   Scheuermann, Ernst Heinrich ^b   Porubsky, Stefan ^c   Kachel, Heinz Georg ^a   Geiger, Helmut ^b   Hauser, Ingeborg A ^b  

^a Transplantationsambulanz   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Focal segmental glomerulosclerosis; Kidney transplantation; Rituximab

Indexed keywords

CREATININE; ENALAPRIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALSARTAN;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA;

ANTIBODIES, MONOCLONAL; BIOPSY; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; NEPHROTIC SYNDROME; PROTEINURIA; RECURRENCE; RENAL DIALYSIS; REOPERATION; TREATMENT OUTCOME;

EID: 34247863962     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00477.x     Document Type: Article

References (30)

1. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005 1: 44.
2. Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transplant 2003 18 (Suppl. 6 68.
3. Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003 18: 1260.
4. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996 334: 878.
5. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994 23: 574.
6. Dall'Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999 34: 1048.
7. Weiner GJ, Link BK. Antibody therapy of lymphoma. Adv Pharmacol 2004 51: 229.
8. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005 31: 456.
9. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005 4: 526.
10. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005 9: 408.
11. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006 19: 621.
12. Pinto J, Lacerda G, Cameron JS, Turner DR, Bewick M, Ogg CS. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981 32: 83.
13. Briggs WA, Gimenez LF, Samaniego-Picota M, et al. Relationship between lymphocyte and clinical steroid responsiveness in focal segmental glomerulosclerosis. J Clin Pharmacol 2000 40: 115.
14. Herve C, Dantal J. Possible new perspectives for our understanding of nephrotic syndrome recurrence. Nephrol Dial Transplant 2006 21: 10.
15. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005 5: 1179.
16. Laufer J, Ettenger RB, Ho WG, Cohen AH, Marik JL, Fine RN. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988 46: 540.
17. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994 330: 7.
18. Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003 41: 1314.
19. Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000 15: 78.
20. Skhiri H, Morelon E, Noel LH, et al. Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transpl Int 2005 18: 458.
21. Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003 75: 810.
22. Raafat RH, Kalia A, Travis LB, Diven SC. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004 44: 50.
23. Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004 19: 794.
24. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. New Engl J Med 2006 354: 1962.
25. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005 20: 1660.
26. Hristea D, Hadaya K, Marangon N, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007 20: 102.
27. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006 6: 859.
28. Youinou P, Hillion S, Jamin C, Pers JO, Saraux A, Renaudineau Y. B lymphocytes on the front line of autoimmunity. Autoimmun Rev 2006 5: 215.
29. Cohen CD, Calvaresi N, Armelloni S, et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005 18: 328.
30. Hippen BE, DeMattos A, Cook WJ, Kew CE 2nd., Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005 5: 2248.